BE1116
Phase 3Small molecule
CSL BehringBE1116 is one of 3 small molecule programs targeting Cardiovascular Surgery. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Cardiovascular Surgery
#DrugCompanyPhaseTrials
1BE1116
CSL BehringPhase 3
Tavist
HHALEON
Preclinical
Sivelestat
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Injury1 trial
Coagulopathy1 trial
Cardiovascular Surgery1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BE1116. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company